Online first
Original article
Published online: 2024-11-14
Implementation of the cardiovascular prevention guidelines in clinical practice. Results from the POLASPIRE II survey
Abstract
Not available
References
- GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403(10440): 2133–2161.
- Jankowski P, Topór-Mądry R, Gąsior M, et al. Management and predictors of clinical events in 75 686 patients with acute myocardial infarction. Kardiol Pol. 2022; 80(4): 468–475.
- Jankowski P, Gąsior M, Gierlotka M, et al. Coordinated care after myocardial infarction. The statement of the Polish Cardiac Society and the Agency for Health Technology Assessment and Tariff System [article in Polish]. Kardiol Pol. 2016; 74(8): 800–811.
- Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019; 26(8): 824–835.
- McEvoy JW, Jennings C, Kotseva K, et al. Variation in secondary prevention of coronary heart disease: The INTERASPIRE study. Eur Heart J. 2024; 45(39): 4184–4196.
- Jankowski P, Kosior DA, Sowa P, et al. Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey. Cardiol J. 2020; 27(5): 533–540.
- Mitkowski P, Witkowski A, Stępińska J, et al. Position of the Polish Cardiac Society on therapeutic targets for LDL cholesterol concentrations in secondary prevention of myocardial infarctions. Kardiol Pol. 2023; 81(7-8): 818–823.
- Krawczyk-Ożóg A, Płotek A, Hołda M, et al. Assessment of the implementation level of the guidelines for secondary prevention of cardiovascular disease in everyday clinical practice. Kardiol Pol. 2021; 79(4): 434–441.
- Ramotowski B, Foryś WJ, Dzida M, et al. Smoking cessation after coronary angiography and percutaneous coronary intervention. Pol Arch Intern Med. 2022; 132(12): 16328.
- Kotseva K, De Bacquer D, Jennings C, et al. Time trends in lifestyle, risk factor control, and use of evidence-based medications in patients with coronary heart disease in Europe: Results from 3 EUROASPIRE surveys, 1999–2013. Glob Heart. 2017; 12(4): 315–322.e3.
- Jankowski P, Kozieł P, Bilo G, et al. Trajectories of blood pressure in patients with established coronary artery disease over 20 years. Int J Hypertens. 2022; 2022: 2086515.
- Jankowski P, Kozieł P, Pająk A. Body mass index and waist circumference in patients with established coronary artery disease over a 20-year period. Cardiol J. 2023; 30(1): 150–152.
- Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2022; 29(1): 5–115.
- Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021; 17(6): 1447–1547.
- Płaczkiewicz-Jankowska E, Czupryniak L, Gajos G, et al. Management of obesity in the times of climate change and COVID-19: an interdisciplinary expert consensus report. Pol Arch Intern Med. 2022; 132(3): 16216.
- Gąsior M, Gierlotka M, Pyka Ł, et al. Temporal trends in secondary prevention in myocardial infarction patients discharged with left ventricular systolic dysfunction in Poland. Eur J Prev Cardiol. 2018; 25(9): 960–969.
- Pająk A, Jankowski P, Zdrojewski T. The burden of cardiovascular disease risk factors: A current problem. Kardiol Pol. 2022; 80(1): 5–15.
- Parma Z, Young R, Roleder T, et al. Management strategies and 5-year outcomes in Polish patients with stable coronary artery disease versus other European countries: data from the CLARIFY registry. Pol Arch Intern Med. 2019; 129(5): 327–334.
- Marcellaud E, Jost J, Tchalla A, et al. Statins in primary prevention in people over 80 years. Am J Cardiol. 2023; 187: 62–73.
- de Ruijter W, Gussekloo J. Cardiovascular prevention in the over-80 age group is not beneficial [article in Dutch]. Ned Tijdschr Geneeskd. 2008; 152(1): 27.
- Kaldal A, Tonstad S, Jortveit J. Sex differences in secondary preventive follow-up after coronary heart events. BMC Cardiovasc Disord. 2023; 23(1): 459.
- Setny M, Jankowski P, Kamiński K, et al. Secondary prevention of coronary heart disease in Poland: Does sex matter? Results from the POLASPIRE survey. Pol Arch Intern Med. 2022; 132(3): 16179.
- Vynckier P, Ferrannini G, Rydén L, et al. Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registry. Eur J Prev Cardiol. 2022; 29(2): 344–351.
- Thalmann I, Preiss D, Schlackow I, et al. Quality of care for secondary cardiovascular disease prevention in 2009–2017: Population-wide cohort study of antiplatelet therapy use in Scotland. BMJ Qual Saf. 2024; 33(11): 716–725.
- Jankowski P, Czarnecka D, Wolfshaut-Wolak R, et al. Age, sex, and secondary prevention of ischaemic heart disease in everyday practice. Kardiol Pol. 2013; 71(12): 1251–1259.
- Jiménez-Quevedo P, Alonso-Martin C, Campuzano Ruiz R, et al. Cardiovascular disease in women: Do we need new diagnostic and therapeutic strategies? Kardiol Pol. 2023; 81(4): 338–349.
- Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 23(11): NP1–NP96.
- Banach M, Jankowski P, Jóźwiak J, et al. PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Arch Med Sci. 2017; 13(1): 1–45.
- Czarnecka D, Jankowski P, Kopeć G, et al. Polish forum for prevention guidelines on hypertension: Update 2017. Kardiol Pol. 2017; 75(3): 282–285.
- Visseren FLJ, Mach F, Smulders YM, et al. Wytyczne ESC 2021 dotyczące prewencji chorób układu sercowo-naczyniowego w praktyce klinicznej. Zeszyty Edukacyjne Kardiol Pol. 2021; 79(V): 1–122.
- Bąk-Sosnowska M, Białkowska M, Bogdański P, et al. Zalecenia kliniczne dotyczące postępowania u chorych na otyłość 2022 – stanowisko Polskiego Towarzystwa Leczenia Otyłości. Med Prakt. ; 2022: 1–87.
- Płaczkiewicz-Jankowska E, Czupryniak L, Strojek K. Rozpoznawanie i leczenie nadczynności tarczycy u kobiet planujących ciążę i kobiet w ciąży. Med Prakt. 2022(3): 39–46.
- Huber CA, Meyer MR, Steffel J, et al. Post-myocardial infarction (MI) care: Medication adherence for secondary prevention after MI in a large real-world population. Clin Ther. 2019; 41(1): 107–117.
- Kubica A, Obońska K, Kasprzak M, et al. Prediction of high risk of non-adherence to antiplatelet treatment. Kardiol Pol. 2016; 74(1): 61–67.
- Swieczkowski D, Mogielnicki M, Cwalina N, et al. Medication adherence in patients after percutaneous coronary intervention due to acute myocardial infarction: From research to clinical implications. Cardiol J. 2016; 23(5): 483–490.
- Kubica A, Kasprzak M, Obońska K, et al. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction. Pharmacology. 2015; 95(1-2): 50–58.
